



Adherium's CEO to present at the Australian Microcap Investment Conference

Melbourne, Australia – 13 October 2022: Adherium Limited ("Adherium" or "the Company"; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce its participation at this year's 11th Annual Australian Microcap Investment Conference, that will be held on Tuesday 18th and Wednesday 19th October 2022 at the Sofitel, Melbourne.

This is Australia's largest and most comprehensive conference focused on emerging ASX listed companies with a market capitalisation under \$300 million, and will showcase their services, products, strategies and people. In addition, this prestigious event provides numerous networking opportunities and is attended by institutional investors, analysts, stockbrokers, family offices, financial planners and experienced investors.

Adherium's presentation is scheduled for Tuesday 18th October at 3:45pm (AEDT) with Chief Executive Officer, Rick Legleiter, who will provide an update on the Company, along with his insights and immediate plans. There will also be a live Q&A session, where investors have the opportunity to ask questions directly.

For more details, please visit: <http://www.microcapconferences.com>

-ENDS-

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence,



supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: WE Communications
WE-AUAdherium@we-worldwide.com